Back to News
Market Impact: 0.2
Charles River Laboratories International Consensus Price Target Increased by 11.46% to $307.39
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Charles River Laboratories International was raised 11.46% to $307.39 per share from $275.80 on September 11, 2026, according to Fintel-compiled estimates. The upward revision signals improved analyst expectations, though it is unlikely to be a major standalone market catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CRL0.45
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October